Skip to main content
OpenTrials
Completed

NCT Number: NCT02748044

Validation of the Utility of Rare Disease Intelligence Platform

The prevention and treatment of diseases via artificial intelligence represents an ultimate goal in computational medicine. The artificial intelligence for systematic clinical application has not yet been successfully validated. Currently, the main prevention strategy for rare diseases is to build specialized care centers. However, these centers are scattered, and their coverage is insufficient, resulting in inadequate health care among a large proportion of rare disease patients. Here, the investigators use "deep learning" to create CC-Cruiser, an intelligence agent involving three functional networks: "pick-up networks" for diagnostics, "evaluation networks" for risk stratification and "strategist networks" to provide assisted treatment decisions. The investigator also establish a cloud intelligence platform for multi-hospital collaboration and conduct clinical trial and website-based study to validate its versatility.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Ophthalmology, First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who underwent ophthalmic examination of the eye and recorded their ocular information in the collaborating hospital.

Exclusion criteria

-

Treatment and study plan

CC-Cruiser

Device

An artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts

Primary outcomes

  1. The proportion of accurate, mistaken and miss detection of CC-Cruiser.

    Time frame: Up to 4 years

Sponsors and collaborators

Lead sponsor

Sun Yat-sen University

Other

Collaborators

  • Ministry of Health, China
  • Xidian University

Registry information

Official study title

Validation of the Utility of Rare Disease Intelligence Platform: A Multicenter Cluster Clinical Trial

Important dates

Study start
2012
Primary completion
2016
Study completion
2016
First posted
Apr 22, 2016
Registry last updated
Apr 22, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.